Abstract #3055

Tumor-targeted alkylphosphocholine chelates for dual-modality PET/MR imaging

Ray R Zhang¹, Christinna L Brunnquell¹, Reinier Hernandez¹, Alan McMillan¹, Anatoly N Pinchuk¹, Paul A Clark², Vincent L Cryns³, John S Kuo², and Jamey P Weichert¹

¹Department of Radiology, University of Wisconsin Madison, Madison, WI, United States, ²Department of Neurological Surgery, University of Wisconsin Madison, Madison, WI, United States, ³Department of Medicine - Endocrinology, University of Wisconsin Madison, Madison, WI, United States

Extensive structure-activity relationships studies have previously shown that alkylphosphocholine (APC) analogs selectively deliver radioiodine and larger fluorophores to a variety of tumor types in rodent models and humans^1-3. To further explore the payload capacity of APCs, we synthesized several new APC-chelates and assessed their ability to deliver Gd (MRI) and ⁶⁴Cu (PET) selectively to tumors in vivo. Prolonged T1-weighted signal enhancement following Gd-DOTA-APC injection was observed in all tumor models. Clinical PET/MR imaging of U87 flank xenograft at 24h and 48h post-administration of Gd-DOTA-APC and ⁶⁴Cu-DOTA-APC demonstrated co-localization of T1-weighted signal enhancement and PET activity in the tumor.

This abstract and the presentation materials are available to members only; a login is required.

Join Here